Sex Subgroup Analyses in Pivotal Clinical Trials of New Drug and Biologic Products Approved by FDA Center for Drug Evaluation and Research in 2014

Chen Alice; Itana Hawi; Xia Guanjun; Pepe Salvatore; Pariser Anne

首页> 外文期刊>Journal of women’s health >Sex Subgroup Analyses in Pivotal Clinical Trials of New Drug and Biologic Products Approved by FDA Center for Drug Evaluation and Research in 2014

【24h】

Sex Subgroup Analyses in Pivotal Clinical Trials of New Drug and Biologic Products Approved by FDA Center for Drug Evaluation and Research in 2014

机译：2014年FDA药物评估和研究中心批准的新药和生物制品关键临床试验中的性别亚组分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of women’s health》 |2015年第4期|共1页
作者
Chen Alice; Itana Hawi; Xia Guanjun; Pepe Salvatore; Pariser Anne;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类妇幼卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Sex Subgroup Analyses in Pivotal Clinical Trials of New Drug and Biologic Products Approved by FDA Center for Drug Evaluation and Research in 2014 [J] . Chen Alice, Itana Hawi, Xia Guanjun, Journal of women’s health . 2015,第4期

机译：2014年FDA药物评估和研究中心批准的新药和生物制品关键临床试验中的性别亚组分析
2. Demographics of Clinical Trials Participants in Pivotal Clinical Trials for New Molecular Entity Drugs and Biologics Approved by FDA From 2010 to 2012 [J] . Eshera Noha, Itana Hawi, Zhang Lei, American journal of therapeutics . 2015,第6期

机译：2010年至2012年间FDA批准的新分子实体药物和生物制剂关键临床试验参与者的临床试验人口统计
3. Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009 [J] . PoonR., KhanijowK., UmarjeeS., Journal of women’s health . 2013,第7期

机译：妇女和性别分析参与FDA于2007-2009年批准的新分子实体药物和生物制剂的后期临床试验
4. Using Machine Learning to Predict the Binding Dissociation of FDA Approved Drugs for Affinity- Based Drug Delivery Applications [C] . Edgardo Rivera-Delgado, Alison Xin, Horst A. von Recum Society for Biomaterials annual meeting and exposition . 2019

机译：使用机器学习预测基于亲和力的药物递送应用的FDA批准药物的结合解离
5. Impact of FDAAA on Registration, Results Reporting, and Publication of Clinical Trials Evaluating New Neuropsychiatric Drugs Approved Between 2005 and 2014 [D] . Zou, Constance Xuanyi. 2019

机译：FDAAA对注册，结果报告和发表临床试验的影响，评估2005年至2014年批准的新神经精神药物
6. Participation of Women and Sex Analyses in Late-Phase Clinical Trials of New Molecular Entity Drugs and Biologics Approved by the FDA in 2007–2009 [O] . Rita Poon, Keshav Khanijow, Sphoorti Umarjee, -1

机译：FDA在2007-2009年批准的新分子实体药物和生物制剂的后期临床试验中的妇女参与和性别分析
7. Participation of Women and Sex Analyses in Late-Phase Clinical Trials of New Molecular Entity Drugs and Biologics Approved by the FDA in 2007–2009 [O] . Rita Poon, Keshav Khanijow, Sphoorti Umarjee, 2013

机译：2007 - 2009年FDA批准的新分子实体药物和生物学的后期临床试验中的妇女和性别分析
8. Advances in FDAs Safety Program for Marketed Drugs: Establishing Premarket Safety Review and Marketed Drug Safety as Equal Priorities at FDAs Center for Drug Evaluation and Research. [R] . 2012

机译：FDas安全计划在市场营销中的应用：在FDas药物评估和研究中心建立上市前安全审查和上市药物安全作为平等优先事项。

Sex Subgroup Analyses in Pivotal Clinical Trials of New Drug and Biologic Products Approved by FDA Center for Drug Evaluation and Research in 2014

著录项

相似文献

相关主题

期刊订阅